Metsera, Inc. (MTSR)
Automate Your Wheel Strategy on MTSR
With Tiblio's Option Bot, you can configure your own wheel strategy including MTSR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MTSR
- Rev/Share 0.0
- Book/Share 6.7936
- PB 6.4369
- Debt/Equity 0.0193
- CurrentRatio 6.5542
- ROIC -0.2777
- MktCap 4594078502.0
- FreeCF/Share -1.6105
- PFCF -38.3466
- PE -20.1794
- Debt/Assets 0.0141
- DivYield 0
- ROE -0.6316
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MTSR | Wells Fargo | -- | Overweight | -- | $65 | June 20, 2025 |
| Initiation | MTSR | BofA Securities | -- | Buy | -- | $38 | Feb. 25, 2025 |
| Initiation | MTSR | Evercore ISI | -- | Outperform | -- | -- | Feb. 25, 2025 |
| Initiation | MTSR | Guggenheim | -- | Buy | -- | $56 | Feb. 25, 2025 |
News
Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Metsera Inc. (MTSR) points to a 55.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Metsera Inc. (MTSR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 89.7% in Metsera Inc. (MTSR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
Published: June 09, 2025 by: Reuters
Sentiment: Positive
Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime.
Read More
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations
Read More
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025
Read More
Metsera to Present at TD Cowen's 45th Annual Health Care Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, from 1:10 – 1:40 p.m. ET.
Read More
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing and a strong safety profile. Positive phase 2a results for MET-097i showed significant mean placebo-adjusted weight loss up to 11.3% without plateau after 12 weeks, with phase 2b and monthly dosing data expected in 2025. MET-233i, a long-acting amylin analog being explored in a phase 1 study, is expected to have a data release in mid-2025.
Read More
About Metsera, Inc. (MTSR)
- IPO Date 2025-01-31
- Website https://metsera.com
- Industry Biotechnology
- CEO Christopher Whitten Bernard
- Employees 93